Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for ...
BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
Morning Overview on MSN
Scientists spot the blood marker shared by people who hit 90+
Across large population studies, people who live into their nineties and beyond keep showing up with the same quiet signature ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback